Bobby Gaspar | Chief Executive Officer and Co-Founder |
Braden Parker | Chief Commercial Officer |
Frank Thomas | President and Chief Operating Officer |
Kevin DeGeeter | Oppenheimer |
Yaron Werber | Cowen |
Pete Stavropoulos | Cantor Fitzgerald |
Gena Wang | Barclays |
Dae Gon Ha | Stifel |
Tess Romero | JPMorgan |
David Hoang | SMBC |
Hello, and welcome to Orchard Therapeutics Fourth Quarter and Year End 2021 Financial Results and Corporate Update Webcast. I’m CEO and Co-Founder, Bobby Gaspar.
Before we get started, I want to remind everyone that this presentation contains forward-looking statements. Please refer to the slide and our latest SEC filings for more information. Three colleagues will be joining me on today’s call; Braden Parker, our Chief Commercial Officer, who many of you know from prior event, is here to discuss early launch execution with Libmeldy and our overall commercial strategy; Frank Thomas, President and Chief Operating Officer is also with us.